On October 7, 2023, the Board of Directors (the ?Board?) of Zevra Therapeutics, Inc. (the ?Company?) appointed Neil F. McFarlane to serve as the Company?s President and Chief Executive Officer, effective October 10, 2023. Concurrently with his appointment as President and Chief Executive Officer, Mr. McFarlane was appointed to serve as a member of the Board. Mr. McFarlane has been designated as the Company?s principal executive officer, succeeding Christal M.M. Mickle., the Company?s former interim President and Chief Executive Officer, in such role.

Ms. Mickle will continue serving in her role as Chief Development Officer. Neil F. McFarlane, age 51, has served as a director of Collegium Pharmaceutical since April 2022. Mr. McFarlane previously served as the Chief Executive Officer and a member of the board of directors of Adamas Pharmaceuticals, Inc. between September 2019 and November 2021, when Adamas was acquired by Supernus Pharmaceuticals, Inc. Mr. McFarlane worked as an independent consultant between June 2019 and August 2019.

From August 2016 to May 2019, Mr. McFarlane served as the Chief Operating Officer of Retrophin, Inc., now known as Travere Therapeutics, Inc., where he was responsible for overseeing operations. From 2011 to 2016 Mr. McFarlane served as Vice President and General Manager of UCB, Inc.'s U.S. Immunology Business Unit and as Vice President for its Global Bone Business Unit in collaboration with Amgen Inc. Prior to his positions at UCB, Mr. McFarlane held positions of increasing responsibility with Genzyme Corporation (?Genzyme?) and Sangstat Medical Corporation prior to its acquisition by Genzyme. Mr. McFarlane previously served as an officer and enlisted soldier in the United States Army Reserves.

He received his B.S. degree and M.S. degree in Nursing from the University of Florida. The Board believes that Mr. McFarlane?s over 25 years of global biopharmaceutical and life sciences experience provide him with the qualifications and skills to serve as a director. On October 10, 2023, Joseph B. Saluri, a member of the Board of the Company, resigned from such position, effectively immediately after the appointment of Mr. McFarlane.